Clinical trials: Localized Breast Carcinoma
Postmastectomy Lymphedema Syndrome, Breast Cancer Surgery Pain
Deep Learning for Musculoskeletal Complications in Breast Cancer
Survival after breast cancer has increased due to early diagnosis and advances in treatment methods. Musculoskeletal problems related to cancer and its treatment constitute a significant part of the daily practice of physiatrists…
- Conditions
- Postmastectomy Lymphedema Syndrome, Breast Cancer Surgery Pain, Osteoporosis Secondary, Shoulder Adhesive Capsulitis
- Trial name
- NCT07236658
- Testing
- physical examination
- Where
- Turkey (Türkiye)
- Volunteers
- 133 people
- Sponsor
- Ankara Etlik City Hospital
Breast Cancer, Brain Metastases
Blood Brain Barrier Disruption (BBBD) Using MRgFUS in the Treatment of Her2-positive Breast Cancer Brain Metastases
The purpose of this study is to evaluate the safety of BBB disruption using the ExAblate 4000-system Type 2 in patients with Her-2 positive breast cancer metastases in the brain.
- Trial name
- BBBD (NCT03714243)
- Testing
- ExAblate BBBD
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- InSightec
Breast Cancer, 2D Mammography
Assessment of Substitution of Focused Cliches and Ultrasound for Tomosynthesis
This study aims to assess if using tomosynthesis for breast cancer surveillance will allow a significant decrease of ultrasound cliches (and radiation exposure)
- Conditions
- Breast Cancer, 2D Mammography, 3D Mammography
- Trial name
- TOMOSEIN (NCT01612650)
- Testing
- tomosynthesis, 2D mammography
- Where
- 4 sites in France
- Volunteers
- 1,069 people
- Sponsor
- Centre Oscar Lambret
Breast Cancer, Triple Negative Breast Cancer
Neoadjuvant Toripalimab Plus Docetaxel and Carboplatin in Patients With Localized TNBC (NeoTOP)
This study aims to investigate efficacy and safety of neoadjuvant toripalimab plus docetaxel and carboplatin in patients with localized triple-negative breast cancer.
- Trial name
- NeoTOP (NCT06618014)
- Testing
- Toripalimab, Docetaxel, Carboplatin
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Sun Yat-sen University
Breast Cancer, Radiation Dermatitis
Efficacy and Safety of Hyperbaric Oxygen Therapy for Radiation Dermatitis in Patients with Localized Breast Cancer
This study aimed to evaluate reducing the incidence of radiation dermatitis by assigning hyperbaric oxygen therapy to patients with localized breast cancer.
- Trial name
- HBOT (NCT06158347)
- Testing
- hyperbaric oxygen chamber
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Ilsan Cha hospital
Breast Neoplasms, Breast Cancer
Paclitaxel-induced Polyneuropathy in Breast Cancer: Early Detection, Risk Factors, Quality of Life and Lifestyle Outcomes
This is a single center prospective observational cohort study that aims to: examine and identify possible risk and susceptibility factors for the incidence and progression of chemotherapy-induced polyneuropathy (CIPN) in female…
- Conditions
- Breast Neoplasms, Breast Cancer, Early-stage Breast Cancer, Non-Metastatic Breast Carcinoma
- Trial name
- CIPN-REBECCA (NCT06052345)
- Testing
- Garmin smartwatch, REBECCA Mobile application, REBECCA PC plug-in
- Where
- Sweden
- Sponsor
- Theodoros Foukakis
Breast Cancer, Colorectal Cancer
Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Breast Cancer, Colorectal Cancer, Gastric Cancer, Liver Cancer
- Trial name
- NCT00553683
- Testing
- cyclophosphamide, poly ICLC, hepatic artery embolization
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Rutgers, The State University of New Jersey
Breast Adenocarcinoma, Prostate Cancer (Adenocarcinoma)
Personalization of External Beam Radiation Therapy in Localised Tumours
The study will include the prospective acquisition of optimized MR imaging data of prostate and breast patients treated with radiotherapy (RT).
- Trial name
- MINIONS (NCT07047495)
- Testing
- prostate patient, breast patients
- Where
- Italy
- Volunteers
- 35 people
- Sponsor
- European Institute of Oncology
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells.
- Conditions
- Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer, Bone Metastases, Carcinoma of the Appendix
- Trial name
- NCT00004074
- Testing
- recombinant interleukin-12, ABI-007/carboplatin/trastuzumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Irinotecan and Capecitabine in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003867
- Testing
- capecitabine, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Montefiore Medical Center
Conditions or Focus of Study: *FDAAA, (Enter 1 to 5 Items)
Breast Cancer Registry in Thailand
Breast cancer is the most common malignancy affecting women. It is the second leading cause of cancer related death in women in many parts of the world.
- Trial name
- NCT01541878
- Where
- Thailand
- Volunteers
- 300 people
- Sponsor
- Siriraj Hospital
Bilateral Breast Carcinoma, HER2-Negative Breast Carcinoma
Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer
This phase Ib trial studies the best dose of berzosertib when given together with the usual treatment (radiation therapy) in treating patients with triple negative or estrogen receptor and/or progesterone receptor positive, HER-2…
- Conditions
- Bilateral Breast Carcinoma, HER2-Negative Breast Carcinoma, Localized Breast Carcinoma, Recurrent Breast Carcinoma
- Trial name
- NCT04052555
- Testing
- Berzosertib, Biospecimen Collection, Quality-of-Life Assessment
- Where
- 14 sites in United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Symptom, Behavioral
YES Study - Newly Diagnosed/Metastatic Intervention
This research study is being done to monitor common symptoms and behavior, and to provide supportive care information and peer support, as well as research opportunities for young women ages of 18-39 years old who have been…
- Trial name
- YES (NCT04379414)
- Testing
- YES portal
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Dana-Farber Cancer Institute
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT Trial
This phase II trial tests how well fezolinetant works in improving vasomotor symptoms (VMS) in breast cancer patients taking endocrine therapy (ET).
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Ductal Carcinoma In Situ
- Trial name
- VEnT (NCT06617455)
- Testing
- Biospecimen Collection, Fezolinetant, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Michigan Rogel Cancer Center
Breast Carcinoma, Endometrial Clear Cell Adenocarcinoma
Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer
This phase II trial studies how well metformin hydrochloride works together with doxycycline in treating patients with localized breast or uterine cancer.
- Conditions
- Breast Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Uterine Corpus Cancer
- Trial name
- NCT02874430
- Testing
- Metformin Hydrochloride, Doxycycline
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Neoplasms, Breast
Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Participants With Breast Cancer
This is an open-label, single-arm pilot study evaluating the antitumor activity and safety of niraparib as neoadjuvant therapy in participants with Human epidermal growth factor receptor 2 (HER2)-negative and breast cancer…
- Trial name
- NCT03329937
- Testing
- Niraparib
- Volunteers
- 21 people
- Sponsor
- Tesaro, Inc.
Breast Cancer, Colorectal Cancer
UMCC 003 Cancer-Related Protein Biomarkers in Blood and Tumor Tissue of Patients With Cancer
RATIONALE: Studying samples of blood and tumor tissue in the laboratory from patients with cancer and blood from healthy participants may help doctors learn more about changes that may occur in DNA and identify biomarkers related…
- Conditions
- Breast Cancer, Colorectal Cancer, Esophageal Cancer, Liver Cancer
- Trial name
- IRB 2000-294 (NCT00900094)
- Testing
- fluorescence in situ hybridization, polymerase chain reaction, protein expression analysis
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Michigan Rogel Cancer Center
Cancer
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
Phase I trial to study the effectiveness of trastuzumab plus R115777 in treating patients who have advanced or metastatic cancer.
- Trial name
- NCT00005842
- Testing
- trastuzumab, tipifarnib
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)